RARX / Ra Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

RARX / Ra Pharmaceuticals, Inc. 15-12B - - 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37926 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in

RARX / Ra Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, L.P. - 13DA4E Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4

Annual Report - 10-K/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

RARX / Ra Pharmaceuticals, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

Bylaws of Ra Pharmaceuticals, Inc.

Exhibit 3.2 BYLAWS OF RA PHARMACEUTICALS, INC. a Delaware Corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such other places both within and without the St

RARX / Ra Pharmaceuticals, Inc. POSASR - - POSASR

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

RARX / Ra Pharmaceuticals, Inc. S-8 POS - - FORM S-8

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

RARX / Ra Pharmaceuticals, Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

Fourth Amended and Restated Certificate of Incorporation of Ra Pharmaceuticals, Inc.

Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RA PHARMACEUTICALS, INC. ARTICLE I NAME The name of the Corporation is Ra Pharmaceuticals, Inc. ARTICLE II REGISTERED OFFICE AND REGISTERED AGENT The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 1

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2020 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Employe

UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients

Exhibit 99.1 UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients · The transaction, which was announced October 10, 2019, will enhance UCB’s potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB’s FcRn targeting

RARX / Ra Pharmaceuticals, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

RARX / Ra Pharmaceuticals, Inc. S-8 POS - - FORM S-8

As filed with the Securities and Exchange Commission on April 2, 2020 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2020 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Employ

Exhibit 10.1

EX-10.1 2 tm2012729d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 87 CambridgePark Drive Cambridge, Massachusetts (the “Building”) SECOND AMENDMENT (“Second Amendment”) EXECUTION DATE: March 11, 2020 LANDLORD: HCP/King 87 CPD LLC, a Delaware limited liability company, successor-in-interest to CPI/King 87 CPD Owner LLC, the successor-in-interest to King 87 CPD LLC TENANT: Ra Pharmaceuticals, Inc., a Delawa

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2020 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Employ

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2020 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Emp

Description of Capital Stock

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Ra Pharmaceuticals, Inc. (the “Company,” “we,” “us” and “our”) summarizes the material terms and provisions of our capital stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our amended and restated certificate of incorpo

Annual Report - 10-K

Use these links to rapidly review the document TABLE OF CONTENTS PART III RA PHARMACEUTICALS, INC.

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Emp

RARX / Ra Pharmaceuticals, Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Emp

RARX / Ra Pharmaceuticals, Inc. DEFM14A - - DEFM14A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RARX / Ra Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) October 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

LICENSE AGREEMENT BY AND BETWEEN CAMURUS AB RA PHARMACEUTICALS INC

Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Execution Copy LICENSE AGREEMENT BY AND BETWEEN CAMURUS AB AND RA PHARMACEUTICALS INC Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be comp

RARX / Ra Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3792

RARX / Ra Pharmaceuticals, Inc. PREM14A - - PREM14A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RARX / Ra Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, L.P. - RA PHARMACEUTICALS, INC. -- SCHEDULE 13D/A - AMEND. NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Ad

Voting and Support Agreement UCB S.A., Certain Stockholders of Ra Pharmaceuticals, Inc. Dated As Of October 9, 2019

Exhibit 99.2 Execution version Voting and Support Agreement Among UCB S.A., And Certain Stockholders of Ra Pharmaceuticals, Inc. Dated As Of October 9, 2019 VOTING AND SUPPORT AGREEMENT dated as of October 9, 2019 (this “Agreement”), among UCB S.A., a société anonyme formed under the Laws of Belgium (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a

RARX / Ra Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74933V108 (CUSIP Number) RA Capital Management, LLC 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2512 Attn: Peter Kol

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 a19-1984918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction o

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases

Exhibit 99.1 UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases · Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting anti

AGREEMENT AND PLAN OF MERGER UCB S.A., FRANQ MERGER SUB, INC. RA PHARMACEUTICALS, INC. DATED AS OF OCTOBER 9, 2019

Exhibit 2.1 Execution version AGREEMENT AND PLAN OF MERGER AMONG UCB S.A., FRANQ MERGER SUB, INC. AND RA PHARMACEUTICALS, INC. DATED AS OF OCTOBER 9, 2019 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitional and Interpretative Provisions 14 ARTICLE 2 THE MERGER 15 SECTION 2.01. The Merger 15 SECTION 2.02. Conversion of Shares 16 SECTION 2.03.

RARX / Ra Pharmaceuticals, Inc. DEFA14A - - 8-K

DEFA14A 1 a19-1984918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdicti

AGREEMENT AND PLAN OF MERGER UCB S.A., FRANQ MERGER SUB, INC. RA PHARMACEUTICALS, INC. DATED AS OF OCTOBER 9, 2019

Exhibit 2.1 Execution version AGREEMENT AND PLAN OF MERGER AMONG UCB S.A., FRANQ MERGER SUB, INC. AND RA PHARMACEUTICALS, INC. DATED AS OF OCTOBER 9, 2019 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitional and Interpretative Provisions 14 ARTICLE 2 THE MERGER 15 SECTION 2.01. The Merger 15 SECTION 2.02. Conversion of Shares 16 SECTION 2.03.

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases

Exhibit 99.1 UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases · Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting anti

Non-Employee Director Compensation Policy

EX-10.2 2 a19-103751ex10d2.htm EX-10.2 Exhibit 10.2 RA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Ra Pharmaceuticals, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of t

RARX / Ra Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37926 RA

4,000,000 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT

Exhibit 1.1 Execution Version 4,000,000 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT July 23, 2019 Jefferies LLC BMO Capital Markets Corp. Stifel, Nicolaus & Company, Incorporated As Representatives of the Several Underwriters, c/o Jefferies LLC 520 Madison Avenue New York, N.Y. 10022 c/o BMO Capital Markets Corp. 3 Times Square, 25th Floor New York, N.Y. 10036 c/o Stifel, N

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Employe

Calculation of Registration Fee Title of each class of securities offered Maximum amount to be registered Amount of registration fee(1) Common Stock, par value $0.001 per share $149,500,000 $18,119.40

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

$100,000,000 Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2019 RA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of incorporation or organizati

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2019 RA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of incorporation or organizati

RARX / Ra Pharmaceuticals, Inc. S-8 S-8

As filed with the Securities and Exchange Commission on May 9, 2019 Registration No.

Calculation of Registration Fee Title of each class of securities offered Maximum amount to be registered Amount of registration fee(1) Common Stock, par value $0.001 per share $100,000,000 $12,120.00

424B5 1 a2238761z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231320 Calculation of Registration Fee Title of each class of securities offered Maximum amount to be registered Amount of registration fee(1) Common Stock, par value $0.001 per share $100,000,000 $12,120.00 (1)

OPEN MARKET SALE AGREEMENTSM

EX-10.1 3 a19-95394ex10d1.htm EX-10.1 Exhibit 10.1 OPEN MARKET SALE AGREEMENTSM May 9, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agen

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of incorporation or organization

RARX / Ra Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q

10-Q 1 a19-7743110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss

RARX / Ra Pharmaceuticals, Inc. S-3ASR S-3ASR

S-3ASR 1 a2238760zs-3asr.htm S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on May 9, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RA PHARMACEUTICALS, INC. (Exact name of registrant as

RA PHARMACEUTICALS, INC. Dated as of , 20 [ ]

EX-4.3 2 a2238760zex-43.htm EX-4.3 Exhibit 4.3 RA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuab

RARX / Ra Pharmaceuticals, Inc. DEFA14A DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

RARX / Ra Pharmaceuticals, Inc. DEF 14A DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SC 13D/A Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 21 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Mor

Subsidiaries of Ra Pharmaceuticals, Inc.

EX-21.1 2 a2237949zex-211.htm EX-21.1 QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 SUBSIDIARIES OF RA PHARMACEUTICALS, INC. Name Jurisdiction of Organization Ownership Percentage Cosmix Verwaltungs GmbH Germany 100 % Ra Europe Limited United Kingdom 100 % Ra Pharmaceuticals Security Corporation USA—MA 100 % QuickLinks Exhibit 21.1 SUBSIDIARIES OF RA PHARMACEUTICAL

RARX / Ra Pharmaceuticals, Inc. 10-K (Annual Report)

10-K 1 a2237949z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART III RA PHARMACEUTICALS, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 Or o TRANSITION REPORT PURSUA

RARX / Ra Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Joint Filing Agreement

EXHIBIT 99 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.

RARX / Ra Pharmaceuticals, Inc. / Novartis Bioventures Ltd - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SCHEDULE 13D/A Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 22 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Mor

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SC 13D/A Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 21 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Mor

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SC 13D/A Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 21 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Mor

RARX / Ra Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, L.P. - RA PHARMACEUTICALS, INC. -- SCHEDULE 13D/A - AMEND. NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Ad

RARX / Ra Pharmaceuticals, Inc. / RA Capital Healthcare Fund LP - SC 13D/A Activist Investment

SC 13D/A 1 tv509220sc13da.htm SC 13D/A OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2018 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001- 37926 26-2908274 (State or other jurisdiction of (Commission (I.R.S. Em

8,387,097 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT

Exhibit 1.1 Execution Version 8,387,097 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT December 11, 2018 Jefferies LLC BMO Capital Markets Corp. Stifel, Nicolaus & Company, Incorporated As Representatives of the Several Underwriters, c/o Jefferies LLC 520 Madison Avenue New York, N.Y. 10022 c/o BMO Capital Markets Corp. 3 Times Square, 25th Floor New York, N.Y. 10036 c/o Stife

8,387,097 Shares Common Stock

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SC 13D/A Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 20 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Mor

Termination of a Material Definitive Agreement

8-K 1 a18-4142718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2018 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001- 37926 26-2908274 (State or other jurisdictio

$100,000,000 Common Stock

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2018 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001- 37926 26-2908274 (State or other jurisdiction of incorporation or organ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 RA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001- 37926 26-2908274 (State or other jurisdiction of incorporation or organ

RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3792

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 a18-3402318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2018 RA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001- 37926 26-2908274 (State or other jurisdicti

RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37926 RA

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2018 RA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001- 37926 26-2908274 (State or other jurisdiction of incorporation or organizat

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2018 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001- 37926 26-2908274 (State or other jurisdiction of incorporation or organizati

Transforming Complement Therapeutics June 2018

Exhibit 99.1 Transforming Complement Therapeutics June 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy, regulatory and clinical progress and therapeutic potential of our product candidates, including RA101495 SC

Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

RA PHARMACEUTICALS, INC. Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT

Exhibit 10.1 RA PHARMACEUTICALS, INC. Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT May 9, 2018 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Ra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2018 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37926 26-2908274 (State or other jurisdiction of incorporation or organization

RARX / Ra Pharmaceuticals, Inc. S-8

As filed with the Securities and Exchange Commission on May 9, 2018 Registration No.

RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

10-Q 1 a18-8675110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss

Non-Employee Director Compensation Policy

Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Ra Pharmaceuticals, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose s

RARX / Ra Pharmaceuticals, Inc. DEFR14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RARX / Ra Pharmaceuticals, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

RARX / Ra Pharmaceuticals, Inc. DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RARX / Ra Pharmaceuticals, Inc. 10-K (Annual Report)

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

RARX / Ra Pharmaceuticals, Inc. / Novo A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V 10 8 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, Esq. Latham & W

RARX / Ra Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, L.P. - RA PHARMACEUTICALS, INC. -- SCHEDULE 13D/A - AMEND. NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Ad

RARX / Ra Pharmaceuticals, Inc. / Novo A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V 10 8 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, Esq. Latham & W

RARX / Ra Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13D/A Activist Investment

OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2009 Washington, D.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K 1 a18-623018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2018 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction

Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Exhibit 99.1 Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock Cambridge, MA.?(BUSINESS WIRE)?February 14, 2018 ? Ra Pharmaceuticals, Inc. (NASDAQ: RARX) (?Ra Pharma?) today announced the pricing of an underwritten public offering of 8,400,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts. Ra Pharma also granted the un

8,400,000 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT

EX-1.1 2 a18-62301ex1d1.htm EX-1.1 Exhibit 1.1 Execution Version 8,400,000 Shares RA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT February 14, 2018 Credit Suisse Securities (USA) LLC Jefferies LLC BMO Capital Markets Corp., As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 c/o Jefferies LLC 520 Madison Ave

8,400,000 Shares Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock

EX-99.1 2 a18-59521ex99d1.htm EX-99.1 Exhibit 99.1 Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA.—(BUSINESS WIRE)—February 13, 2018 — Ra Pharmaceuticals, Inc. (NASDAQ: RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. Ra Pharma expec

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

8-K 1 a18-595218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2018 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction

Subject to Completion Preliminary Prospectus Supplement dated February 13, 2018

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

RARX / Ra Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Joint Filing Agreement

EXHIBIT 99 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.

RARX / Ra Pharmaceuticals, Inc. / Novartis Bioventures Ltd - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

Exhibit 99.1 Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria - Dosing Complete, Primary Endpoint Met in Eculizumab Na?ve Cohort (p=0.002 for LDH reduction) - Switch Cohort: Interim Data Demonstrate Successful Switching from Eculizumab - Phase 2 Enrollment Complete in All Cohorts - Company to Host Conference Call Today,

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 4, 2017 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction of incorporation) (Commissi

RA101495 SC Phase 2 PNH Program Update December 4, 2017

Exhibit 99.2 RA101495 SC Phase 2 PNH Program Update December 4, 2017 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy, regulatory and clinical progress and therapeutic potential of our product candidates, including RA

RARX / Ra Pharmaceuticals, Inc. S-3/A

As filed with the Securities and Exchange Commission on November 14, 2017. Registration No. 333-221266 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-2908274 (State or other jurisdiction of incorpora

RARX / Ra Pharmaceuticals, Inc. ESP

RA PHARMACEUTICALS, INC. 87 Cambridge Park Drive Cambridge, MA 02140 November 9, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ra Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-221266 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 193

RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3792

Form of indenture for subordinated debt securities and the related form of subordinated debt security

Exhibit 4.2 RA PHARMACEUTICALS, INC. Issuer AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form o

Power of Attorney

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 1, 2017.

Form of indenture for senior debt securities and the related form of senior debt security

Exhibit 4.3 RA PHARMACEUTICALS, INC. Issuer AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Secu

RARX / Ra Pharmaceuticals, Inc. / Novo A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V 10 8 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, Esq. Latham & W

RARX / Ra Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) July 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

RARX / Ra Pharmaceuticals, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37926 RA

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2017 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction of incorporation) (Commission

Ra Pharmaceuticals S-8

As filed with the Securities and Exchange Commission on May 11, 2017 Registration No.

Ra Pharmaceuticals 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37926 RA

Ra Pharmaceuticals DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Ra Pharmaceuticals DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Next Generation Therapeutics for Disorders of Complement Regulation April 2017

Exhibit 99.1 Next Generation Therapeutics for Disorders of Complement Regulation April 2017 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product candidates, including RA

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2017 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction of incorporation) (Commission

RARX / Ra Pharmaceuticals, Inc. 10-K - Annual Report - 10-K

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

RARX / Ra Pharmaceuticals, Inc. / Lightstone Ventures, L.P. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs

RARX / Ra Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

International PNH Interest Group Annual Meeting American Society of Hematology Scientific Sessions Manchester Grand Hyatt, San Diego CA Friday 2nd December 2016

EX-99.1 2 a16-225211ex99d1.htm EX-99.1 Exhibit 99.1 International PNH Interest Group Annual Meeting American Society of Hematology Scientific Sessions Manchester Grand Hyatt, San Diego CA Friday 2nd December 2016 Introducing RA101495: A Novel Subcutaneously-Administered Peptide Inhibitor of C5 for PNH Blocks C5 cleavage and production of C5a and C5b Phase 1 data in healthy volunteers shows rapid,

Ra Pharmaceuticals 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2016 Ra Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37926 26-2908274 (State or other jurisdiction of incorporation) (Commissi

Ra Pharmaceuticals 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3792

Amended and Restated By-laws of the Registrant, as currently in effect

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF RA PHARMACEUTICALS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place ma

Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect

Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “RA PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE THIRTY-FIRST DAY OF OCTOBER, A.D. 2016, AT 12:22 O`CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF

RARX / Ra Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13D Activist Investment

SC 13D 1 v452620sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

RARX / Ra Pharmaceuticals, Inc. / MORGENTHALER VENTURE PARTNERS IX LP - SC 13D Activist Investment

CUSIP NO. 74933V108 13D Page 1 of 20 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.)* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V108 (CUSIP Number) Travis Boettner Morge

RARX / Ra Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - SCHEDULE 13D - RA PHARMACEUTICALS, INC. Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 74933V108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Add

August 17, 2016

EX-99.B EXHIBIT B August 17, 2016 Ra Pharmaceuticals, Inc. 87 Cambridge Park Dr. Cambridge, MA 02140 Credit Suisse Securities (USA) LLC Jefferies LLC BMO Capital Markets Corp. As Representatives of the several Underwriters c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o BMO Capital Markets Corp. 3 Times Squ

RARX / Ra Pharmaceuticals, Inc. / Novo A/S - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ra Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933V 10 8 (CUSIP Number) Thomas Dyrberg Novo A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, Esq. Latham & Watkins LL

RARX / Ra Pharmaceuticals, Inc. / Novartis Bioventures Ltd - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

EVIDENCE OF SIGNATURE AUTHORITY

EXHIBIT 99.1 EVIDENCE OF SIGNATURE AUTHORITY Excerpt from Commercial Register of Novartis AG Identification number Legal status Entry Cancelled Carried CH-270.3.002.061-2 from: 1 CHE-103.867.266 Limited or Corporation 01.03.1996 on: All entries In Ca Business name Ref Legal seat 1 Novartis AG 1 Basel 1 2 2 (Novartis SA) (Novartis Inc.) CHE-103.867.266 Novartis AG Basel 5 All entries In Mo Ca Perso

Joint Filing Agreement

EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock of Ra Pharmaceuticals, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be

POWER OF ATTORNEY

EXHIBIT 99.2 POWER OF ATTORNEY We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Simon Zivi, Laurieann Chaikowsky, Michael Jones, David Middleton, Bartosz Dzikowski, Markus Goebel and Reinhard Ambros and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our

7,049,230 Shares Ra Pharmaceuticals, Inc. Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No.

Ra Pharmaceuticals S-8

As filed with the Securities and Exchange Commission on October 26, 2016 Registration No.

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Simon Zivi, Laurieann Chaikowsky, Michael Jones, David Middleton, Bartosz Dzikowski, Markus Goebel and Reinhard Ambros and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our

Ra Pharmaceuticals S-1MEF

S-1MEF 1 a16-167219s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on October 25, 2016. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 26-2908274 (State or other jurisdicti

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pharmaceuticals, Inc. (th

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas A. Treco, David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pha

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of David Charles Lubner, Kingsley L. Taft, Ryan Sansom and Benjamin Piper, signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 RA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-2908274 (State of incorporation or organization) (I.R.S. Employer Identification No.) 87 Cambridge Park D

Ra Pharmaceuticals ESP

Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 VIA EDGAR October 21, 2016 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attention: Scot Foley RE: Ra Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-213917 Dear Mr. Foley: Pursuant to Rule 461 under the Securities Ac

Ra Pharmaceuticals ESP

VIA EDGAR October 21, 2016 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

Ra Pharmaceuticals S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on October 17, 2016.

Ra Pharmaceuticals ESP

Goodwin Procter LLP Counselors at Law 100 Northern Ave. Boston, MA 02210 T: 617.570.1000 F: 617.523.1231 October 14, 2016 VIA EDGAR AND OVERNIGHT DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Suzanne Hayes Scot Foley Sasha Parikh Lisa Vanjoske Re: Ra Pharmaceuticals, Inc. Registration Statement on Form S-1 (the ?Regis

Ra Pharmaceuticals S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on October 13, 2016.

Ra Pharmaceuticals ESP

October 13, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.

Ra Pharmaceuticals ESP

Goodwin Procter LLP Counselors at Law 100 Northern Ave. Boston, MA 02210 T: 617.570.1000 F: 617.523.1231 October 7, 2016 FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 Telephone: (617) 401-4060 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENTIAL TRE

Ra Pharmaceuticals S-1

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on September 30, 2016.

Ra Pharmaceuticals A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 23, 2016, as Amendment No.

Ra Pharmaceuticals TR

September 23, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.

Ra Pharmaceuticals

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 17, 2016.